Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 8, 2009, Pages 3347-3352

  Nguyen, Katherine T ^a   Ta, Philip ^a   Bich, Thu Hoang ^a   Cheng, Shaoji ^a,c   Hao, Binghua ^a,c   Nguyen, M Hong ^a,b,c   Clancy, Cornelius J ^a,b,c,d,e  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d VA Pittsburgh Healthcare System   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CELL ADHESION; CELL DAMAGE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; FUNGICIDAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA; CANDIDA ALBICANS; CELL LINE; CELL LINE, TUMOR; CELL WALL; ECHINOCANDINS; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, TRANSMISSION; PHAGOCYTOSIS;

EID: 67749091130     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01480-08     Document Type: Article

References (25)

1. Angiolella, L., B. Maras, A. R. Stringaro, G. Arancia, F. Mondello, A. Girolamo, A. T. Palamara, and A. Cassone. 2005. Glucan-associated protein modulations and ultrastructural changes of the cell wall in Candida albicans treated with micafungin, a water-soluble, lipopeptide antimycotic. J. Chemother. 17:409-416.
2. Balashov, S. V., S. Park, and D. S. Perlin. 2006. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob. Agents Chemother. 50:2058-2063.
3. Borg-von Zepelin, M., K. Zaschke, U. Gross, M. Monod, and F. M. Müller. 2002. Effect of micafungin (FK463) on Candida albicans adherence to epithelial cells. Chemotherapy 48:148-153.
4. Cheng, S., C. J. Clancy, Z. Zhang, B. Hao, W. Wang, K. A. Iczkowski, M. A. Pfaller, and M. H. Nguyen. 2007. Uncoupling of oxidative phosphorylation enables Candida albicans to resist killing by phagocytes and persist in tissue. Cell. Microbiol. 9:492-501.
5. Cheng, S., C. J. Clancy, M. A. Checkley, Z. Zhang, K. L. Wozniak, K. R. Seshan, H. Y. Jia, P. Fidel, Jr., G. Cole, and M. H. Nguyen. 2005. The role of Candida albicans NOT5 in virulence depends upon diverse host factors in vivo. Infect. Immun. 73:7190-7197.
6. Cheng, S., C. J. Clancy, M. A. Checkley, M. Handfield, J. D. Hillman, A. Progulske-Fox, A. S. Lewin, P. L. Fidel, and M. H. Nguyen. 2003. Identification of Candida albicans genes induced during thrush offers insight into pathogenesis. Mol. Microbiol. 48:1275-1288.
7. Clancy, C. J., H. Huang, S. Cheng, H. Derendorf, and M. H. Nguyen. 2006. Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments. Antimicrob. Agents Chemother. 50:2569-2572.
8. Clinical and Laboratory Standards Institute. 2007. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. Approved standard M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Ernst, E. A., M. E. Klepser, and M. A. Pfaller. 2000. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob. Agents Chemother. 44:1108-1111.
10. Ernst, M. E., M. E. Klepser, E. J. Wolfe, and M. A. Pfaller. 1996. Antifungal dynamics of LY303366, an investigational echinocandin B analog, against Candida spp. Diagn. Microbiol. Infect. Dis. 26:125-131.
11. Klepser, M. E., E. J. Ernst, R. E. Lewis, M. E. Ernst, and M. A. Pfaller. 1998. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob. Agents Chemother. 42: 1207-1212.
12. Krause, D. S., A. E. Simje, C. van Rensburg, J. Viljoen, T. J. Walsh, B. P. Goldstein, M. Wible, and T. Henkel. 2004. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin. Infect. Dis. 39:770-775.
13. Kuse, E. R., P. Chetchotisakd, C. A. da Cunha, M. Runke, C. Barrios, D. Raghunadharao, J. S. Sekhon, A. Freire, V. Ramasubramanian, I. Demeyer, M. Nucci, A. Leelarasamee, F. Jacobs, J. Decruyenaere, D. Pittet, A. J. Ullmann, L. Ostrosky-Zeichner, O. Lortholary, S. Koblinger, H. Diekmann-Berndt, and O. A. Cornely. 2007. Micafungin versus liposomal amphotericin B for candidemia and invasive candidiasis: a phase III randomized double-blind trial. Lancet 369:1519-1527.
14. Li, Y., M. H. Nguyen, H. Derendorf, S. Cheng, and C. J. Clancy. 2007. Measurement of voriconazole activity against Candida albicans, C. glabrata and C. parapsilosis isolates using time-kill methods validated by high-performance liquid chromatography. Antimicrob. Agents Chemother. 51:2985-2987.
15. Lin, D., L. C. Wu, M. G. Rinaldi, and P. F. Lehmann. 1995. Three distinct genotypes within Candida parapsilosis from clinical sources. J. Clin. Microbiol. 33:1815-1821.
16. Manavathu, E. K., M. S. Ramesh, I. Baskaran, L. T. Ganesan, and P. H. Chandrasekar. 2004. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans. J. Antimicrob. Chemother. 53:386-389.
17. Mora-Duarte, J., R. Betts, C. Rotstein, A. L. Colombo, L. Thompson-Moya, J. Smietana, R. Lupinacci, C. Sable, N. Kartsonis, and J. Perfect. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-2029.
18. Park, S., R. Kelly, J. N. Kahn, J. Robles, M. J. Hsu, E. Register, W. Li, V. Vyas, H. Fan, G. Abruzzo, A. Flattery, C. Gill, G. Chrebet, S. A. Parent, M. Kurtz, H. Teppler, C. M. Douglas, and D. S. Perlin. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49:3264-3273.
19. Pfaller, M. A., D. J. Diekema, L. Ostrosky-Zeichner, J. H. Rex, B. D. Alexander, D. Andes, S. D. Brown, V. Chaturvedi, M. A. Ghannoum, C. C. Knapp, D. J. Sheehan, and T. J. Walsh. 2008. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol. 46:2620-2629.
20. Pfaller, M. A., L. Boyken, R. J. Hollis, J. Kroeger, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2008. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 46:150-156.
21. Pfaller, M. A., D. J. Diekema, S. A. Messer, R. J. Hollis, and R. N. Jones. 2003. In vitro activities of anidulafungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob. Agents Chemother. 47:1068-1071.
22. Reboli, A. C., C. Rotstein, P. G. Pappas, S. W. Chapman, D. H. Kett, D. Kumar, R. Betts, M. Wible, B. P. Goldstein, J. Schranz, D. S. Krause, and T. J. Walsh. 2007. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 356:2472-2482.
23. Roling, E. E., M. E. Klepser, A. Wasson, R. E. Lewis, E. J. Ernst, and M. A. Pfaller. 2002. Antifungal activities of fluconazole, anidulafungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods. Diagn. Microbiol. Infect. Dis. 43:13-17.
24. Soustre, J., M. H. Rodier, S. Imbert-Bouyer, G. Daniault, and C. Imbert. 2004. Caspofungin modulates in vitro adherence of Candida albicans to plastic coated with extracellular matrix proteins. J. Antimicrob. Chemother. 53:522-525.
25. Wheeler, R. T., and G. R. Fink. 2006. A drug-sensitive genetic network masks fungi from the immune system. PLOS Pathog. 2:e35.